Self-testing for Hepatitis C screening in high-risk and general populations
Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population
This study tests whether self-testing for Hepatitis C using a simple kit can help both high-risk individuals and the general public get screened more easily, especially with support from healthcare providers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1384 (estimated) |
| Sex | All |
| Sponsor | University of La Laguna Academic / other |
| Locations | 1 site (La Laguna, Santa Cruz De Tenerife) |
| Trial ID | NCT05146609 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the acceptance and effectiveness of self-testing for Hepatitis C using dried blood spot (DBS) testing. It involves participants from drug dependence centers and the general population, who will receive a self-testing kit along with instructions. The study aims to determine if support from healthcare providers increases participation rates and to identify factors that influence participation. A total of 346 patients from each group will be recruited to assess the impact of this self-testing approach.
Who should consider this trial
Good fit: Ideal candidates include individuals who have previously contacted drug dependence centers or those from primary care centers.
Not a fit: Patients who have had a negative HCV serology or viral load in the last year will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance Hepatitis C screening rates, particularly among high-risk populations, leading to earlier diagnosis and treatment.
How similar studies have performed: Previous studies have shown promise in self-testing approaches for screening, suggesting potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * All subjects who have contacted a drug dependence center between 2013 and 2017, as well as patients from a group of a primary care center. * Signed informed consent. Exclusion criteria: * Patient's refusal to participate in the study. * Negative HCV serology or viral load in the last year. * Death. * Belonging to another health area * Not having the patient's address in the hospital's computer system.
Where this trial is running
La Laguna, Santa Cruz De Tenerife
- Complejo Hospitalario Universitario de Canarias — La Laguna, Santa Cruz De Tenerife, Spain (Recruiting)
Study contacts
- Study coordinator: Manuel Hernandez-Guerra, MD
- Email: mhernand@ull.edu.es
- Phone: +34922678559
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.